NIKKEI 225
38,620.99 -325.94 (-0.84%) HANG SENG
19,261.64 +41.02 (+0.21%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,417.40 -8.50 (-0.35%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,907.51 -859.34 (-1.54%)
Exelixis, Inc. (EXEL)
After hours:
- Zacks
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
- Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
ALAMEDA, Calif., May 20, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. The first case (Civil Action N
- Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif., May 07, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:
